https://investors.biontech.de/de/news-releases/news-release-details/pfizer-und-biontech-beginnen-phase-12-studie-mit-erstem-mrna
Raymond James Maintains Outperform on First Bancorp, Lowers Price Target to $41
Raymond James analyst David Long maintains First Bancorp (NASDAQ:FBNC) with a Outperform and lowers the price target from $43 to $41.